Enzastaurin
Authors:
- Steven T RosenSRSteven T Rosen
- 1 November 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 19 (6) , 590-595
Abstract
Enzastaurin - a novel oral antitumor agent that selectively inhibits protein kinase Cbeta activity - has demonstrated promise in phase I and II trials in various advanced cancers, and is being investigated in multiple hematologic malignancies and solid tumors. Enzastaurin (LY317615) was initially developed as an antiangiogenic cancer therapy. Subsequent preclinical studies showed its antitumor effect by inhibiting tumor proliferation and inducing apoptosis on multiple cancer cell lines as well as xenograft models. Enzastaurin not only inhibits protein kinase Cbeta activity but also suppresses signaling through the phosphoinositide-3 kinase/AKT pathway. Based on the phase I study, 525 mg/day is the recommended dose for oral enzastaurin. It is well tolerated at this dose, with no clinically significant grade 3 or 4 toxicities. A recent phase II study of enzastaurin in patients with relapsed or refractory diffuse large B-cell lymphoma showed enzastaurin to be associated with prolonged freedom from progression. Several preliminary studies showed promising results in patients with various advanced cancers and suggested that enzastaurin can be safely used long term in combination with traditional chemotherapies. Enzastaurin is emerging as a promising new antitumor treatment. This review addresses the mechanism of action, development, preclinical studies, and clinical study results with enzastaurin.Keywords
This publication has 24 references indexed in Scilit:
- Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2007
- Protein Kinase C β Enhances Growth and Expression of Cyclin D1 in Human Breast Cancer CellsCancer Research, 2006
- B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CβIIBlood, 2006
- Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2006
- Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphomaLaboratory Investigation, 2005
- The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma XenograftsCancer Research, 2005
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learningNature Medicine, 2002
- Protein kinase C inhibitors as novel anticancer drugsExpert Opinion on Investigational Drugs, 2001
- Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migrationBlood, 2001
- Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth.Journal of Clinical Investigation, 1996